Ala67Thr mutation in the poliovirus receptor CD155 is a potential risk factor for vaccine and wild-type paralytic poliomyelitis

Journal of Medical Virology

Volumn 81, Issue 5, 2009, Pages 933-936

  Kindberg, Elin ^a,b   Ax, Cecilia ^a   Fiore, Lucia ^c   Svensson, Lennart ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Paralytic poliomyelitis; Poliovirus; Poliovirus receptor; Vaccine associated paralytic poliomyelitis

Indexed keywords

ALANINE; POLIOMYELITIS VACCINE; THREONINE; UNCLASSIFIED DRUG; VIRUS RECEPTOR; VIRUS RECEPTOR CD155;

ADULT; AGED; APOPTOSIS; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; FEMALE; GENOTYPE; HOMOZYGOSITY; HUMAN; ITALY; MALE; MUTATION RATE; PARALYSIS; PARALYTIC POLIOMYELITIS; PARESIS; POLIOMYELITIS; POLIOMYELITIS VIRUS; POLYMERASE CHAIN REACTION; PYROSEQUENCING; RECEPTOR GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS RESISTANCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; GENOTYPE; HUMANS; INFANT; ITALY; MALE; MIDDLE AGED; MUTATION; PARALYSIS; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RECEPTORS, VIRUS; RISK FACTORS; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

POLIOVIRUS;

EID: 65649101836     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21444     Document Type: Article

References (19)

1. Aoki J, Koike S, Ise I, Sato-Yoshida Y, Nomoto A. 1994. Amino acid residues on human poliovirus receptor involved in interaction with poliovirus. J Biol Chem 269:8431-8438.
2. Buttinelli G, Donati V, Fiore S, Marturano J, Plebani A, Balestri P, Soresina AR, Vivarelli R, Delpeyroux F, Martin J, Fiore L. 2003. Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis. J Gen Virol 84:1215-1221.
3. de Oliveira LH, Struchiner CJ. 2000. Vaccine-associated paralytic poliomyelitis: A retrospective cohort study of acute flaccid paralyses in Brazil. Int J Epidemiol 29:757-763.
4. Destombes J, Couderc T, Thiesson D, Girard S, Wilt SG, Blondel B. 1997. Persistent poliovirus infection in mouse motoneurons. J Virol 71:1621-1628.
5. Fiore L, Novello F, Simeoni P, Amato C, Buttinelli G, Fiore S, Vellucci L, De Stefano D, Grandolfo ME, Luzzi I. 2000. Epidemiology of acute flaccid paralysis in Italy: 1996-98. Group for the Study of AFP. Ann Ig 12:99-110.
6. Gosselin AS, Simonin Y, Guivel-Benhassine F, Rincheval V, Vayssiere JL, Mignotte B, Colbere-Garapin F, Couderc T, Blondel B. 2003. Poliovirus-induced apoptosis is reduced in cells expressing a mutant CD155 selected during persistent poliovirus infection in neuroblastoma cells. J Virol 77:790-798.
7. Karttunen A, Poyry T, Vaarala O, Ilonen J, Hovi T, Roivainen M, Hyypia T. 2003. Variation in enterovirus receptor genes. J Med Virol 70:99-108.
8. Khetsuriani N, Prevots DR, Quick L, Elder ME, Pallansch M, Kew O, Sutter RW. 2003. Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. J Infect Dis 188:1845-1852.
9. Kindberg E, Hejdeman B, Bratt G, Wahren B, Lindblom B, Hinkula J, Svensson L. 2006. A nonsense mutation (428G-> A) in the fucosyltransferase FUT2 gene affects the progression of HIV-1 infection. AIDS 20:685-689.
10. Lasch EE, Joshua H, Gazit E, El-Massri M, Marcus O, Zamir R. 1979. Study of the HLA antigen in Arab children with paralytic poliomyelitis. Isr J Med Sci 15:12-13.
11. Melnick JL. 1996. Current status of poliovirus infections. Clin Microbiol Rev 9:293-300.
12. Nathanson N. 2008. The pathogenesis of poliomyelitis: What we don't know. Adv Virus Res 71:1-50.
13. Pavio N, Couderc T, Girard S, Sgro JY, Blondel B, Colbere-Garapin F. 2000. Expression of mutated poliovirus receptors in human neuroblastoma cells persistently infected with poliovirus. Virology 274:331-342.
14. Picard C, Casanova JL, Abel L. 2006. Mendelian traits that confer predisposition or resistance to specific infections in humans. Curr Opin Immunol 18:383-390.
15. Racaniello VR. 2006. One hundred years of poliovirus pathogenesis. Virology 344:9-16.
16. Rosche B, Cepok S, Stei S, Vogel F, Grummel V, Hoffmann S, Kroner A, Maurer M, Rieckmann P, Sommer N, Hemmer B. 2004. The role of the polio virus receptor and the herpesvirus entry mediator B genes for the development of MS. J Neuroimmunol 156:171-177.
17. Saunderson R, Yu B, Trent RJ, Pamphlett R. 2004. A polymorphism in the poliovirus receptor gene differs in motor neuron disease. Neuroreport 15:383-386.
18. Strebel PM, Sutter RW, Cochi SL, Biellik RJ, Brink EW, Kew OM, Pallansch MA, Orenstein WA, Hinman AR. 1992. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 14:568-579.
19. van Eden W, Persijn GG, Bijkerk H, de Vries RR, Schuurman RK, van Rood JJ. 1983. Differential resistance to paralytic poliomyelitis controlled by histocompatibility leukocyte antigens. J Infect Dis 147:422-426.